Why IMU is a multi multi bagger, page-25383

AZER-CEL OFF-THE-SHELF (ALLOGENEIC) CAR T

Why has Imugene management prioritised Azer-cel in the last 4 months presentations?

Are they quietly confident of the data to date, as they say, first-to-market potential,
currently in Phase 1b trial potential for registrational Phase 2/3 trial for FDA approval.
Azer-cel could be the first approved allogeneic CAR T therapy for patients with DLBCL who
failed autologous CAR T.

In addition to the above study, pre-clinical studies at City of Hope have started, combining Azer-cel with Imugene's onCARlytics (CF33-CD19), generating FDA data.

Deep dive into Allogeneic CAR T - recent article Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10814647/

Regards.